Market capitalization | $3.68m |
Enterprise Value | $-160.00k |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.10 |
EV/Sales (TTM) EV/Sales | -0.01 |
P/S ratio (TTM) P/S ratio | 0.27 |
P/B ratio (TTM) P/B ratio | 0.69 |
Revenue growth (TTM) Revenue growth | 11.81% |
Revenue (TTM) Revenue | $13.55m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Sonoma Pharmaceuticals, Inc.:
1 Analyst has issued a forecast Sonoma Pharmaceuticals, Inc.:
Sep '24 |
+/-
%
|
||
Revenue | 14 14 |
12%
12%
|
|
Gross Profit | 5.22 5.22 |
34%
34%
|
|
EBITDA | -4.12 -4.12 |
19%
19%
|
EBIT (Operating Income) EBIT | -4.28 -4.28 |
21%
21%
|
Net Profit | -3.69 -3.69 |
40%
40%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sonoma Pharmaceuticals, Inc. engages in identifying, developing, and commercializing therapies for chronic skin conditions. The company offers solutions in dermatology, animal healthcare, and advanced tissue care product areas. Its products target skin diseases including acne, atopic dermatitis, scarring, infections, itch, pain, and harmful inflammatory responses. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Petaluma, CA.
Head office | United States |
CEO | Amy Trombly |
Employees | 172 |
Founded | 1999 |
Website | www.sonomapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.